3 results
Our study aim is to assess whether MARIA* can provide diagnostic information that can supplement, and in some cases, replace mammography as a tool in the symptomatic workflow. We will also seek patient feedback on this non-ionising, non-compressing…
Primary: The co-primary objectives of this study are* to compare independently adjudicated progression-free survival (PFS) following treatment with neratinib pluscapecitabine versus lapatinib plus capecitabine in patients with HER2-positive (HER2+)…
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…